How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers

Qianhui Hua; Hong Xu; Xinyi Chen; Junhang Pan; Ying Peng; Wei Wang; Bin Chen; Jianmin Jiang

doi:10.3389/fpubh.2021.736632

How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers

Front Public Health. 2021 Nov 24:9:736632. doi: 10.3389/fpubh.2021.736632. eCollection 2021.

Authors

Qianhui Hua¹, Hong Xu², Xinyi Chen³, Junhang Pan³, Ying Peng³, Wei Wang³, Bin Chen³, Jianmin Jiang^{3

4}

Affiliations

¹ School of Medicine, Ningbo University, Ningbo, China.
² Department of Tuberculosis Control and Prevention, Xiaoshan District Center for Disease Control and Prevention, Hangzhou, China.
³ Department of Tuberculosis Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
⁴ Key Laboratory of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Hangzhou, China.

Abstract

To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated through stakeholder survey and interview. The attitudes toward three RR-TB screening strategies were statistically different: inclination to choose who to screen (Z = 98.477; P < 0.001), funding for rapid diagnostic technology screening either by reimbursed health insurance or directly subsidized financial assistance (Z = 4.142, P < 0.001), and respondents' attitude during RR-TB screening implementation levels (Z = 2.380, P = 0.017). In conclusion, RR-TB screening scope could be expanded by applying rapid diagnostic technologies. Provinces with different economic status could adjust their screening policies accordingly.

Keywords: attitudes; policy; rifampin-resistant tuberculosis; screening; stakeholders.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Mass Screening
Rifampin / therapeutic use
Tuberculosis* / diagnosis
Tuberculosis* / prevention & control
Tuberculosis, Multidrug-Resistant* / diagnosis

Substances

Rifampin